Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
7 Best Pharmaceutical Stocks to Buy Now
06:00pm, Wednesday, 20'th Jul 2022
These investments represent the best pharmaceutical stocks. Each offers incredible upside potential in the post-pandemic world.
European Commission Signs COVID-19 Drug Procurement Deal With Gilead
12:43pm, Tuesday, 19'th Jul 2022
Gilead Sciences Inc (NASDAQ: GILD) and the European Commission signed a joint procurement agreement for rapid and equitable access to the COVID-19 therapeutic Veklury (remdesivir). This is the seco
Should You Invest in the VanEck Biotech ETF (BBH)?
10:20am, Tuesday, 19'th Jul 2022 Zacks Investment Research
Sector ETF report for BBH
Gilead Sciences - Improving Here
07:41pm, Friday, 15'th Jul 2022
Gilead Sciences started 2022 on a solid foot, as the original outlook for the year was quite underwhelming. This is comforting, yet the composition of the beat, driven by stronger pandemic related sal
Gilead Sciences: Today Until 2030 - Making The Bull Case
04:20pm, Friday, 15'th Jul 2022
Gilead Sciences has endured a difficult few years as its share price has performed worse than any major US pharma. The company is trying to rebuild under new CEO Daniel O'Day, an oncology expert.
This New Regulation Could Juice Pfizer Stock Even More
12:55pm, Friday, 15'th Jul 2022 The Motley Fool
Pharmacists will be able to prescribe Paxlovid now.
Humanigen (HGEN) Plunges as COVID Study Fails to Meet Goal
03:37pm, Thursday, 14'th Jul 2022 Zacks Investment Research
The NIAID's ACTIV-5/BET-B study evaluating Humanigen's (HGEN) lenzilumab plus remdesivir in hospitalized COVID-19 patients fails to meet the primary endpoint. Stock down.
Pandemic is still a public health emergency, warns WHO, urging greater surveillance including testing and sequencing
11:04am, Thursday, 14'th Jul 2022 MarketWatch
The World Health Organization said Tuesday the coronavirus pandemic remains a public health emergency, and warned that a reduction in surveillance, including testing and sequencing, is making it diffi
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022
02:07pm, Wednesday, 13'th Jul 2022 Benzinga
Upgrades
For The Shyft Group Inc (NASDAQ:SHYF), DA Davidson upgraded the previous rating of Neutral to Buy. Shyft Group earned $0.06 in the first quarter, compared to $0.36 in the year-ago quarter. Th
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
10:20am, Wednesday, 13'th Jul 2022 Zacks Investment Research
Smart Beta ETF report for IBB
Gilead Sciences (GILD) Stock Moves -0.51%: What You Should Know
09:50pm, Tuesday, 12'th Jul 2022 Zacks Investment Research
In the latest trading session, Gilead Sciences (GILD) closed at $62.34, marking a -0.51% move from the previous day.
Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
04:05pm, Tuesday, 12'th Jul 2022
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2022 financial results will be released on Tuesday, August 2, after the m
How to Earn $10,000 a Year in Passive Retirement Income
03:00pm, Sunday, 10'th Jul 2022 The Motley Fool
You'll either need a decent chunk of change or some patience.
How to Earn $10,000 a Year in Passive Retirement Income
11:00am, Sunday, 10'th Jul 2022
You'll either need a decent chunk of change or some patience.
This Company Could Ease the Pain in a Bear Market
02:23pm, Saturday, 09'th Jul 2022 The Motley Fool
New product candidates aim to diversify into areas with a large unmet medical need.
